Restoration of a Conduction Block after the Long-term Treatment of CIDP with Anti-neurofascin 155 Antibodies: Follow-up of a Case over 23 Years

We herein report a woman with chronic inflammatory demyelinating polyneuropathy (CIDP) in whom positivity for anti-neurofascin 155 antibodies was revealed 23 years after the onset of neuropathy. The patient initially reported numbness in the face at 50 years of age and subsequently manifested features compatible to typical CIDP. Steroid administration initiated at 54 years of age ameliorated her neuropathic symptoms. Although the nerve conduction indices at 59 years of age deteriorated, those at 68, 72, and 73 years of age showed a gradual recovery. The deterioration and subsequent restoration of compound muscle action potential amplitudes was the most dramatic, suggesting that a conduction block can be reversed earlier than other electrophysiological indices.

[1]  D. Sherman,et al.  Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies , 2017, Neuromuscular Disorders.

[2]  J. Devaux,et al.  Teaching NeuroImages: Cranial nerve hypertrophy in IgG4 anti-neurofascin 155 antibody–positive polyneuropathy , 2017, Neurology.

[3]  G. Sobue,et al.  Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies , 2017, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  E. Nagata,et al.  IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay , 2016, Journal of Neuroimmunology.

[5]  J. Devaux,et al.  Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. , 2016, Brain : a journal of neurology.

[6]  N. Kokubun,et al.  Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy , 2016, Neurology.

[7]  A. Hiwatashi,et al.  Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy , 2015, Annals of clinical and translational neurology.

[8]  R. Rojas-García,et al.  Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[9]  N. Yuki,et al.  Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. , 2015, Brain : a journal of neurology.

[10]  S. Dib-Hajj,et al.  Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  H. Watanabe,et al.  Muscle atrophy in chronic inflammatory demyelinating polyneuropathy: a computed tomography assessment , 2014, European journal of neurology.

[12]  R. Blesa,et al.  Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg , 2014, Neurology.

[13]  G. Nogales-Gadea,et al.  Antibodies to contactin‐1 in chronic inflammatory demyelinating polyneuropathy , 2013, Annals of neurology.

[14]  J. Schwab,et al.  Neurofascin as a target for autoantibodies in peripheral neuropathies , 2012, Neurology.

[15]  C. Sommer,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition , 2010, The Lancet Neurology.

[16]  J. Pollard,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision , 2010, European journal of neurology.

[17]  M. Bhat,et al.  Spatiotemporal ablation of myelinating glia‐specific neurofascin (NfascNF155) in mice reveals gradual loss of paranodal axoglial junctions and concomitant disorganization of axonal domains , 2009, Journal of neuroscience research.

[18]  H. Watanabe,et al.  Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndrome , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[19]  M. Kubota,et al.  Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  G. Sobue,et al.  Age associated axonal features in HNPP with 17p11.2 deletion in Japan , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  Elior Peles,et al.  Contactin Orchestrates Assembly of the Septate-like Junctions at the Paranode in Myelinated Peripheral Nerve , 2001, Neuron.

[22]  K. Petry,et al.  Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. , 2000, Ultrastructural pathology.

[23]  M. Noda,et al.  IgG Anti‐GM1 antibody is associated with reversible conduction failure and axonal degeneration in guillain‐barré syndrome , 1998, Annals of neurology.

[24]  J. Mcleod,et al.  Chronic relapsing polyneuritis , 1976, Journal of the Neurological Sciences.

[25]  P. Dyck,et al.  Chronic inflammatory polyradiculoneuropathy. , 1975, Mayo Clinic proceedings.

[26]  C. Krarup,et al.  Chronic inflammatory demyelinative polyneuropathy. , 2013, Handbook of clinical neurology.